Max Delbrück Center
Register
Register
Register

PartnershipUpdated on 23 November 2025

Small molecules inhibiting SARS-coronavirus infections

Group Leader at Max Delbrück Center for Molecular Medicine

Berlin, Germany

About

Using a novel assay, we have screened a 100.000 compound library for molecules inhibiting the binding of SARS-CoV2 to its receptor ACE2 and identified and validated 6 hits, which are optimized further by medicinal chemistry. The objective is to develop an inexpensive, preventive, oral or inhalative drug for COVID-19 and other coronavirus infections.

Looking for

  • Joint development
  • Technology transfer

Organisation

Max Delbrück Center for Molecular Medicine

University / Research Organisation

Berlin, Germany

Similar opportunities